A5078406133- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
- Hematopoietic Stem Cell Transplantation
- Genomic variations and chromosomal abnormalities
- Lung Cancer Research Studies
- Fungal Infections and Studies
- Chronic Myeloid Leukemia Treatments
- Prenatal Screening and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Child and Adolescent Health
- Adolescent and Pediatric Healthcare
- Human Health and Disease
- Hematological disorders and diagnostics
- Neonatal Health and Biochemistry
- Childhood Cancer Survivors' Quality of Life
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cutaneous lymphoproliferative disorders research
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2013-2024
Ministry of Health of the Russian Federation
2010-2024
City Clinical Hospital No 31
2013
Russian Children's Clinical Hospital
2010-2013
Regional Children's Clinical Hospital No. 1
2013
Nizhny Novgorod Regional Clinical Hospital named after Semashko
2013
Pediatric mature B-cell non-Hodgkin lymphomas (B-NHLs) are highly aggressive malignant tumors that curable with chemotherapy (ChT). High-dose methotrexate (MTX) is considered indispensable for successful treatment, but this therapy frequently induces severe mucositis and infectious complications, especially in induction, which can cause treatment failure. A prospective multicenter trial of combined immunochemotherapy advanced-stage B-NHL rituximab the modified NHL-BFM-90 protocol was...
The results of two consecutive multicenter clinical trials enrolled 241 patient with childhood mature B-cells non-Hodgkin lymphomas/leukemia are presented. Patients received treatment according B-NHL 2004mab protocol (n = 83) and 2010M 158) combined immunochemotherapy (ICT) in Russian Belarus pediatric clinics from 2004 to 2015 years. Primary patients different (Burkitt lymphoma/leukemia, diffuse large B-cell lymphoma primary mediastinal (DLBCL PMBCL)) aged 2 18 years included the studies....
Acute promyelocytic leukemia (APL) pathogenesis is based on RARA gene translocations, which are of high importance in the diagnosis and proper therapy selection for APL. However, some cases acute myeloid (AML) demonstrates APL-like morphological features such as atypical promyelocytes accumulation. This type AML characterized by involvement other RAR family members or completely different genes. In present study, we used conventional karyotyping, FISH high-throughput sequencing a group 271...
Over the past years, outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to use intensive chemotherapy, more effective supportive therapy, and availability allogeneic hematopoietic stem cell transplantation. This article presents children AML treated in accordance AML-MM-2006 protocol. Our study was approved by Independent Ethics Committee Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. The included 233 a median...
The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This due both to the difficulties achieving a second remission and problems organizing allogeneic bone marrow transplantation (BMT) those patients who need it. standard approach use second-line drugs regime high-dosage chemotherapy blocks, but response rate for this treatment with early relapses remains low response time short. Recently, new drugs with different mechanisms action have appeared that...
Lineage switch is a rare phenomenon in which transition from lymphoid to myeloid was observed relapse of acute leukemia, or vice versa. This paper presents the four clinical case reports lymphoblastic leukemia with MLL gene rearrangement (KMT2A) phenotype relapse.
The achievement of clinical and hematological remission at the end induction therapy is one key treatment response parameters in pediatric acute myeloid leukemia (AML). Besides conventional cytomorphological evaluation bone marrow (BM) blast count, minimal residual disease (MRD) measurement has been widely applied routine practice recent years. aim study was to compare results flow cytometric MRD with BM investigation when assessing children AML. approved by Independent Ethics Committee...
Bone marrow tumor blasts immunophenotyping is an essential part of Burkitt lymphoma/leukemia (BL) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL) differential diagnostics. Nevertheless immunoglobulin heavy light chains detection on the cell surface could meet several biological methodological pitfals. Thus aim present study was development additional BL immunophenotypic criteria. Leukemic antigen profile in 21 cases 84 children with BCP-ALL compared a retrospective way. Antigen...
The prognostic role of HL in AML children is a matter discussion. 185 patients were treated for our center, 36 had (19.5%). study was approved by the Independent Ethics Committee Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology, and Immunology. Median Le 97 × 109 /l (50–428 ± /l). Standard risk group 4 pts, intermediate – 8, hight 24. most common variants M4/M5 FAB classification 30 pts genetic rearrangement MLL 15 pts. Thirty-five with received cytoreduction...
This article is dedicated to one of the auto-respiratory syndromes – adenosine deaminase deficiency 2 (deficiency DADA2) in 12-year-old. rare disease caused by mutations ADA2 gene (CECR1), that encodes protein. Clinical manifestations DADA2 are very diverse and usually include systemic inflammatory reaction form fever attacts, vasculopathy livedo reticulum, polyarteritis nodosa, ischemic and/or hemorrhagic strokes, as well signs immunodeficiency with hypogammaglobulinemia bone marrow...
The aim of this study was to describe the immunophenotype leukemic cells in acute myeloid leukemia (AML) with inv(16) (p13.1q22)/CBFb-MYH11 and t(16;16)(p13.1;q22)/CBFb-MYH11 children. This is supported by Independent Ethics Committee approved Academic Council Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. We investigated bone marrow samples from 36 pediatric patients initially diagnosed AML inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFb-MYH11....
Acute megakaryocytic leukemia (AML M7) – a rare disease characterized by poor treatment response, except for t(1;22) variant in infants. Cytogenetic abnormalities AML M7 are highly heterogeneous. We collected samples from children with to analyze the disease cytogenetic profile. During September 2009 March 2012 20 patients was studied using fluorescence situ hybridization. Complex and heterogeneous chromosomal were revealed. It found that no recurring and cytogenetic markers unique each...
Infants of the first year life represent a unique group patients with acute myeloid leukemia (AML). Materials and methods research: characteristics 492 newly diagnosed AML aged 10 DoL-18 y/o who received intensive chemotherapy according to AML-MM-2006 AML-MRD-2018 guidelines in Apr. 2007-Apr. 2021 were analyzed. The analysis was carried out separately for infants (<1 y/o, 58/12%), young children (1-3 99/20%) 3-18 (335/68%). Results: infant characterized by higher incidence...
Infants of the first year life represent a unique group patients with acute myeloid leukemia (AML). Materials and methods research: characteristics 492 newly diagnosed AML aged 10 DoL-18 y/o who received intensive chemotherapy according to AML-MM-2006 AML-MRD-2018 guidelines in Apr. 2007-Apr. 2021 were analyzed. The analysis was carried out separately for infants (<1 y/o, 58/12%), young children (1-3 99/20%) 3-18 (335/68%). Results: infant characterized by higher incidence...
Presently, there is no consensus on the best treatment for relapsed B-cell acute lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with extramedullary lesions. There are certain anti-tumor drugs that can be used case of relapse allo-HSCT, however, prospective randomized studies directly comparing different chemotherapy and immunotherapy approaches generally lacking. Retrospective exploring therapy disease difficult...
The diagnosis of rare hematological disorders requires a comprehensive clinical and laboratory investigation with careful interpretation all test results. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one such entities. We have performed retrospective analysis the results immunophenotyping, cytomorphology cytogenetics bone marrow tumor cells from 5 patients BPDCN aged 8 to 51 years. study was approved by Independent Ethics Committee Dmitry Rogachev National Medical Research Center...